KALA BIO, Inc. (KALA): restructuring charge — KALA halts pipeline, cuts 51% of staff, grants retention bonuses to top executives

KALA BIO, Inc.

Ceased development of KPI-012 and stem cell platform; workforce reduced by ~19 employees (~51%).
Expects ~$0.4M in restructuring costs (severance/benefits), substantially in Q4 2025.
Entered retention agreements: CEO Todd Bazemore ($183,750), CFO Mary Reumuth ($136,250), CMO Kim Brazzell ($145,000).
Company preserving cash while exploring strategic alternatives.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

KALA BIO, Inc. announced a restructuring with charges of approximately $0.4 million affecting KPI-012 and its mesenchymal stem cell secretome platform (approximately 19 employees, or approximately 51%).

Type: restructuring
Charge: approximately $0.4 million
Affected area: KPI-012 and its mesenchymal stem cell secretome platform
Headcount: approximately 19 employees, or approximately 51%

Exact text from the filing

generally accepted accounting principles as a result of the Reduction. Subsequent to the Original Report, the Company determined that it expects to incur costs of approximately $0.4 million related to the Reduction, primarily consisting of severance payments and employee benefit costs. The costs related to the Reduction are expected to be substantially incurred in

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

KALA BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-096071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.